Evolva and Lehvoss sign agreement for resveratrol ingredient distribution in Europe
04 Oct 2023 --- Swiss biotech company Evolva and Lehvoss Group Nutritional Division have signed a distribution agreement involving the use of Veri-te Resveratrol in dietary supplements. The deal is expected to generate roughly CHF 1.5 million (US$1.6 million) in sales by its conclusion in 2025.
The Evolva branded ingredient will be distributed through Lehvoss subsidiaries across Europe, with more than 12 countries covered under the agreement.
“Veri-te Resveratrol is a responsible multi-functional ingredient with proven health benefits supported by a number of clinical studies. We consider Lehvoss to be an ideal partner for the distribution of Veri-te Resveratrol due to its market capabilities,” says Anne de Vos, chief commercial officer at Evolva.
Priming polyphenolic compounds
The agreement aims to strengthen distribution in a key market following the successful entry of Veri-te Resveratrol into Southeast Asian countries and Brazil for foods and dietary supplements.
Veri-te Resveratrol is the main pillar of Evolva’s Health Ingredients business and was a key driver of the 14% revenue growth recorded in the first half of 2023.
Resveratrol is a polyphenolic compound from low concentrations of grapes, peanuts, cranberries and other berries. Veri-te Resveratrol is a high-purity ingredient, steeped using fermentation, which ensures a stable, traceable and reliable supply.
Evolva and Lehvoss will distribute Veri-te Resveratrol across Europe.
“We are thrilled to add this high-quality, researched and sustainable brand to our portfolio. We are convinced that Veri-te Resveratrol will add strength to our specially selected offer of ingredients across Europe,” says Teresita Rudà, head of brands and marketing for Lehvoss Nutrition.
Novel Food approval
The ingredient is Novel Food approved and can be used in different grades of dietary supplements, functional beverages, cosmetics and pharma applications.
Healthy living trends are spurring demand for functional ingredients and nature-based supplements, according to Evolva, which reported a 46% growth in its health ingredients segment in 2021.
Earlier this year, Evolva pursued strategic transactions after entering into negotiations with its financing partner, Nice & Green. The discussions involve a different interpretation of the company’s financing terms.
The company’s Q3 results for 2022 showed that it tripled its revenue with a 250% increase compared to the same timeframe in 2021. The company saw a revenue increase of 56% on a year-to-date basis, amounting to CHF 11.3 million (US$12 million).
Meanwhile, Lehvoss Nutrition released a plant-based line for its existing PlantNutra brand, which includes blends of fruits, berries, greens, vegetables and plant enzymes.
Edited by Inga de Jong
